ALK and non-small cell lung carcinoma: One limitation of the present study was that, despite ALK-targeted TKIs being the standard first-line treatment for advanced NSCLC that is positive for ALK-rearrangements, most patients in our study were treated with platinum-based chemotherapy, which may have affected the clinical and radiographic features of patients with MBM.